Raymond James Financial Services Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Raymond James Financial Services Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,518	Closed	-$53K	–	2965
2019 Q1	$53K	Sell	11,518 -1,645	-12%	-$7.79K	﹤0.01%	2703
2018 Q4	$46K	Sell	13,163 -904	-6%	-$6.28K	﹤0.01%	2477
2018 Q3	$142K	Buy	14,067 +2,987	+27%	+$23.8K	﹤0.01%	2612
2018 Q2	$80K	Buy	+11,080	New	+$77.3K	﹤0.01%	2639
2016 Q2	–	Sell	-60,554	Closed	-$968K	–	2360
2016 Q1	$968K	Buy	+60,554	New	+$1.15M	0.01%	920

Other funds holding INSY

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Raymond James Financial Services Advisors's INSY Position: Q2 2019 in Review

Raymond James Financial Services Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 11,518 shares — an estimated $53K sold.

Raymond James Financial Services Advisors first reported a position in INSY in Q1 2016 and held it in 5 quarters. The position peaked at $968K in Q1 2016. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

Raymond James Financial Services Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 11,518 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $53K.
Raymond James Financial Services Advisors first reported a position in Insys Therapeutics, Inc. in Q1 2016 and held it in 5 quarters.
Raymond James Financial Services Advisors's Insys Therapeutics, Inc. position peaked at $968K in Q1 2016.
16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.